IBT
EXEL icon

International Biotechnology Trust’s Exelixis EXEL Stock Holding History

International Biotechnology Trust’s Portfolio EXEL Stock Details EXEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-543,000
Closed -$10.5M – 69
2023
Q1 		$10.5M Hold
543,000
– – 2.94% 9
2022
Q4 		$8.71M Hold
543,000
– – 2.69% 13
2022
Q3 		$8.51M Buy
543,000
+535,710
+7,349% +$10.4M 2.73% 12
2022
Q2 		$350K Buy
+7,290
New +$150K 3.65% 8
2021
Q4 		– Sell
-489,534
Closed -$10.3M – 79
2021
Q3 		$10.3M Buy
489,534
+388,000
+382% +$7.21M 2.49% 13
2021
Q2 		$1.85M Sell
101,534
-785,000
-89% -$18.3M 0.49% 40
2021
Q1 		$20M Buy
886,534
+360,000
+68% +$8.13M 5.3% 5
2020
Q4 		$10.6M Hold
526,534
– – 2.89% 15
2020
Q3 		$12.9M Buy
526,534
+74,000
+16% +$1.73M 4.15% 8
2020
Q2 		$10.3M Buy
452,534
+349,000
+337% +$8.09M 3.42% 12
2020
Q1 		$1.78M Hold
103,534
– – 0.81% 23
2019
Q4 		$1.82M Hold
103,534
– – 0.66% 35
2019
Q3 		$1.83M Sell
103,534
-340,000
-77% -$6.88M 0.85% 28
2019
Q2 		$9.48M Buy
443,534
+200,000
+82% +$4.19M 3.52% 10
2019
Q1 		$5.79M Sell
243,534
-346,000
-59% -$7.89M 2.14% 17
2018
Q4 		$9.11M Sell
589,534
-115,000
-16% -$2.05M 5.65% 6
2018
Q3 		$9.57M Buy
704,534
+260,000
+58% +$5.07M 4.55% 7
2018
Q2 		$9.57M Buy
444,534
+56,200
+14% +$1.16M 3.67% 9
2018
Q1 		$8.6M Sell
388,334
-22,000
-5% -$608K 3.35% 11
2017
Q4 		$12.5M Buy
410,334
+156,000
+61% +$4.15M 4.4% 5
2017
Q3 		$6.16M Buy
254,334
+47,334
+23% +$1.26M 2.4% 13
2017
Q2 		$5.1M Buy
207,000
+76,000
+58% +$1.61M 1.94% 15
2017
Q1 		$2.84M Sell
131,000
-54,000
-29% -$1.1M 1.09% 25
2016
Q4 		$2.76M Buy
+185,000
New +$2.67M 1.24% 20

Other funds holding EXEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

International Biotechnology Trust's EXEL Position: Q2 2023 in Review

International Biotechnology Trust sold out of Exelixis (EXEL) in Q2 2023, closing a stake of 543,000 shares — an estimated $10.5M sold.

International Biotechnology Trust first reported a position in EXEL in Q4 2016 and held it in 24 quarters. The position peaked at $20M in Q1 2021. 379 funds tracked by Wall St. Rank hold EXEL as of Q2 2023.

  • International Biotechnology Trust reported no remaining Exelixis position as of Q2 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 543,000 Exelixis shares in Q2 2023, an estimated $10.5M.
  • International Biotechnology Trust first reported a position in Exelixis in Q4 2016 and held it in 24 quarters.
  • International Biotechnology Trust's Exelixis position peaked at $20M in Q1 2021.
  • 379 funds tracked by Wall St. Rank held Exelixis as of Q2 2023.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.